1 **Heme is crucial for medium-dependent metronidazole resistance in clinical isolates of *C. difficile***

2 Ilse M. Boekhoud^{1,2}, Igor Sidorov¹, Sam Nooij^{1,3}, Céline Harmanus¹, Ingrid M.J.G. Bos-

3 Sanders¹, Virginie Viprey⁴, Bill Spittal⁴, Emma Clark⁴, Kerrie Davies⁴, Jane Freeman⁴, Ed

4 J. Kuijper^{1,5}, Wiep Klaas Smits^{1,2,3}

5

6 On behalf of the COMBACTE-CDI Consortium and the European Study Group for

7 *Clostridioides difficile*

8

9 ¹Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands;

10 ²Netherlands Centre for One Health, The Netherlands;

11 ³Center for Microbiome Analyses and Therapeutics, Leiden University Medical Center, Leiden, The
12 Netherlands;

13 ⁴Healthcare Associated Infections Research Group, School of Medicine, University of Leeds, Leeds,
14 United Kingdom;

15 ⁵National Institute for Public Health and the Environment, Bilthoven, The Netherlands

16 ORCID: IMB 0000-0002-6579-7124, IAS 0000-0001-6519-4983, SN 0000-0001-5892-5637, CH 0000-

17 0002-5328-3273, KD 0000-0001-6862-5355, JF 0000-0001-9580-4586, EJK 0000-0001-5726-2405,

18 WKS 0000-0002-7409-2847

19 **Abstract**

20 Until recently, metronidazole was the first-line treatment for *Clostridioides difficile* infection and it is
21 still commonly used. Though resistance has been reported due to the plasmid pCD-METRO, this does
22 not explain all cases. Here, we investigate resistance to metronidazole in a collection of clinical
23 isolates of *C. difficile*. We find that nearly all isolates demonstrate a heme-dependent increase in the
24 minimal inhibitory concentration for metronidazole, which in some cases leads to isolates being
25 qualified as resistant (MIC > 2 mg/L). Moreover, whole genome sequence analysis reveals a single
26 nucleotide polymorphism in the heme responsive gene *hsmA*, which defines a metronidazole
27 resistant lineage of PCR ribotype 010 / multilocus sequence type 15 isolates that also includes pCD-
28 METRO containing strains. Together our data demonstrate that heme is crucial for medium-
29 dependent metronidazole resistance in *C. difficile*.

30 Introduction

31 *Clostridioides difficile* is a gram-positive, anaerobic enteropathogen capable of causing a *C. difficile*
32 infection (CDI) upon disruption of the normal intestinal microbiota by for instance antimicrobial
33 therapy.^{1,2} It is the primary cause of nosocomial diarrhea, but is also found in cases of community-
34 acquired disease.^{2,3} Although the use of antibiotics is a risk factor for CDI, antimicrobials are also
35 used to treat the infection. Until recently, metronidazole was considered the drug-of-choice for
36 treatment of mild CDI. Though vancomycin and fidaxomicin are currently indicated as first-line
37 therapeutics for the treatment of CDI,^{4,5} metronidazole is still commonly used.^{6,7}

38 Our understanding of the mechanisms of resistance to metronidazole in *C. difficile* is still limited. For
39 Clostridia, studies are complicated by reports of unstable, inducible metronidazole resistance which
40 is lost upon removal of antibiotic pressure or after the strain undergoes freeze-thawing cycles.^{8,9}
41 Recently, however, we have demonstrated that metronidazole resistance in diverse strains of *C.*
42 *difficile* can be mediated by the plasmid pCD-METRO through a mechanism that is not yet
43 understood.¹⁰ Notably, the presence of pCD-METRO explains at least part of independently reported
44 cases of metronidazole resistance.¹¹⁻¹³ However, strains that lack pCD-METRO can still be resistant
45 to metronidazole. For instance, we have previously identified a pCD-METRO negative strain that
46 demonstrated medium-dependent metronidazole resistance.¹⁰ This suggests that other, potentially
47 chromosomal, determinants contribute to resistance.

48 Information on pathways that could contribute to resistance comes from laboratory strains with
49 evolved resistance to metronidazole. Using a laboratory-evolved PCR ribotype (RT) 027 strain
50 exhibiting stable metronidazole resistance, mutations were identified in genes affecting electron
51 transport and iron utilisation, but the individual contribution of these mutations to the resistance
52 phenotype was not further investigated.¹⁴ More recently, a mutator strain defective in DNA
53 mismatch repair was evolved in the presence of metronidazole.¹⁵ The study discovered mutations in
54 a gene encoding an iron transporter (*feoB1*) in metronidazole resistant strains and showed that

55 sequential mutations in *nifH* (encoding the pyruvate-ferredoxin oxidoreductase, PFOR), *xdh*
 56 (encoding xanthine dehydrogenase) or *iscR* (encoding an iron-sulfur cluster regulator) could further
 57 increase metronidazole resistance.¹⁵ Though studies with laboratory evolved strains are informative,
 58 it is unclear how these findings translate to metronidazole resistant strains isolated from subjects
 59 outside the laboratory.

60 Here, we leverage the potential of strains collected within a project to develop a detailed
 61 understanding of the epidemiology and clinical impact of CDI across Europe (COMBACTE-CDI) that
 62 were investigated for metronidazole resistance. Four strains demonstrated stable metronidazole
 63 resistance, but lacked pCD-METRO. We show that there is a heme-dependent increase in the
 64 minimal inhibitory concentration (MIC) for metronidazole across PCR ribotypes and that a higher
 65 MIC, at least in a subset of strains, correlates with a specific mutational signature in the gene *hsmA*.

66 **Materials and methods**

67 **Strain characterisation**

68 The strains analysed here were collected as part of the COMBACTE-CDI study. Strains were
 69 characterised by PCR ribotyping following the *C. difficile* Ribotyping Network of England and
 70 Northern Ireland protocol and tested for metronidazole susceptibility in agar dilution experiments at
 71 the Healthcare Associated Infection group of the University of Leeds, United Kingdom.^{16, 17}
 72 Confirmation of PCR ribotype and additional susceptibility testing was performed at the Netherlands
 73 Reference Laboratory of *C. difficile*, hosted at the Leiden University Medical Center, The
 74 Netherlands.¹⁸ Use of the strains for the present study was approved by the Management Board of
 75 the COMBACTE-CDI Consortium. Strains were further characterised by whole genome sequencing
 76 (see below).

77 Metronidazole minimal inhibitory concentrations were determined using the agar dilution method
 78 according to CLSI guidelines on either Wilkins-Chalgren agar (in Leeds) or Brucella Blood Agar (BBA)
 79 (in Leiden).¹⁹ Although no formal breakpoints have been defined, we used the EUCAST
 80 epidemiological cutoff of 2 mg/L to define metronidazole resistance in *C. difficile* in this study.²⁰

81 **Determining medium-dependent metronidazole resistance**

82 Agar plates on which *C. difficile* was grown were always incubated anaerobically at 37°C in a Don
 83 Whitley A55 workstation (10% CO₂, 10% H₂ and 80% N₂ atmosphere). For determining medium-
 84 dependent metronidazole resistance, *C. difficile* strains were first grown on reduced Brain Heart
 85 Infusion (BHI) agar plates supplemented with 0.5% yeast extract (Sigma-Aldrich) and *Clostridium*
 86 *Difficile* Selective Supplements (CDSS, Oxoid) for 24-48 hours. From these plates bacterial
 87 suspensions corresponding to 2.0 McFarland turbidity were made in PBS. These suspensions were
 88 then applied on BBA plates (bioMérieux) or on BHI agar supplemented with 0.5% yeast extract and
 89 when applicable with 1 µg/ml vitamin K (Sigma-Aldrich), 5% sheep blood (Thermo Fisher Scientific)

90 and/or 5 µg/ml hemin (Sigma-Aldrich). Metronidazole or vancomycin E-tests (bioMérieux) were then
91 applied and growth was evaluated after 48 hours of anaerobic incubation. Pictures were taken with
92 an Interscience Scan 500 Automatic colony counter.

93 **Whole genome sequencing and signature analysis**

94 As part of the COMBACTE-CDI project, DNA extracts of the selected isolates were processed for
95 whole genome sequencing at GSK Bio, as per their standard operating procedures. Briefly, total
96 genomic DNA's were quantitated using Quant-iT dsDNA High-Sensitivity Assay Kit (Life technologies)
97 and SYNERGY H1 microplate reader. Sequencing libraries were prepared from 1 ng of DNA using the
98 Nextera XT DNA Library Prep kit (Illumina) and libraries concentrations were normalised using bead
99 normalisation as described by the manufacturer. Sequencing was performed on the Illumina MiSeq
100 platform with MiSeq v3 600-cycles kit or on the Illumina NextSeq 500 platform with NextSeq 550
101 High-Output v 2.5 300-cycles kit. FASTQ files passed the quality control checks and strain
102 identification confirmation (*C. difficile*), as performed in the BIOMERIEUX EPISEQ® CS beta platform
103 (<https://www.biomerieux-episeq.com/>).

104 For the SNP analysis, reads were mapped to the *hsmA*, *hsmR*, *hatT* and *hatR* genes obtained from
105 the reference sequence of strain R20291 (GenBank entry FN545816.1). Mapping of reads to the
106 reference sequences was done with Bowtie2 tool (version 2.3.4, options: --local --qc-filter) and
107 results of this mapping were analysed using Samtools (version 1.7, default options) and depth of the
108 reads coverage was calculated using IGV tool (version 2.3.98, options: -w 1).²¹⁻²³ Average depth
109 calculated for all positions of the analysed isolates is shown in Supplementary Table 1. Values of
110 depth of coverage obtained for each position (nucleotides or indels) for all samples were filtered
111 using a minimum coverage of 5 reads for each position. Mapping results for all positions were
112 compared between all strains. Positions where at least one strain has a mutation or variation
113 compared to the corresponding reference sequence were included in the generation of the genetic
114 signature of *hsmA*, *hsmR*, *hatT* and *hatR*.

115 **Phylogenetic analysis**

116 ST15 and 15-like publicly available whole-genome sequencing data (Supplemental Table 2) were
 117 selected based on a previous analysis, and corresponding FASTQ files were downloaded from the
 118 SRA (n=85).²⁴ wgSNP analysis was performed on the Enterobase platform with a selected minimum
 119 frequency threshold of 0.1.^{25,26} Three entries were excluded from the analysis, as they did not pass
 120 the quality control of the Enterobase platform (Supplemental Table 2).²⁶ A wgSNP maximum
 121 likelihood tree was generated with RaxML and tree branches were represented in a log scale for
 122 clarity.²⁷

Results

Metronidazole resistance is observed in the COMBACTE-CDI strain collection

The Combatting Bacterial Resistance in Europe – *Clostridioides difficile* infections (COMBACTE-CDI) is a multi-centre European-wide project with an aim to provide detailed understanding of the epidemiology and clinical impact of CDI across the whole healthcare economy in Europe. Sites testing both in-patient and community samples were recruited from 12 countries across Europe. All diarrheal faecal samples (regardless of tests requested by physician) were submitted to a central laboratory (Leeds, UK) on two selected days between July and November 2018. From these samples *C. difficile* was isolated and tested by PCR ribotyping. The metronidazole Minimum Inhibitory Concentration (MIC) for 213 clinical isolates (Belgium n=3, France n=4, Greece n=4, Ireland n=1, Italy n=23, Netherlands n=8, Poland n=29, Romania n=37, Slovakia n=1, Spain n=43, Sweden n=12, UK n=48) were determined by Wilkins-Chalgren agar dilution.¹⁷ Of these, 22 isolates (10%) were found to be resistant to metronidazole using the EUCAST criteria as a cut-off (MIC $\geq$ 2 mg/L) and were sent to the *C. difficile* reference laboratory of the Leiden University Medical Center for further study.²⁰ When possible, an RT-matched isolate with an MIC<2 mg/L from the COMBACTE-CDI collection was also provided. PCR ribotypes submitted were RT002 (n=3); RT010 (n=7); RT016 (n=1); RT018 (n=3); RT027 (n=12); RT176 (n=1); RT181 (n=4) and RT198 (n=1) (Table 1).

As metronidazole is generally quite rare, our findings underscore the importance for investigating large collections of clinical isolates to enrich for strains that are resistant, in order to investigate possible underlying causes of resistance.

Low level resistance to metronidazole is not due to carriage of the pCD-METRO plasmid

We further investigated the clinical isolates from the COMBACTE-CDI strain collection (n=32; Table 1). To correct for interlaboratory differences and to make the results directly comparable to our

previous study,¹⁰ we performed PCR ribotyping and antimicrobial susceptibility testing by agar dilution according to CLSI standards on Brucella Blood agar (BBA) in a second laboratory.^{10, 28} A single strain showed discrepant results in PCR ribotyping and was therefore excluded from further analysis. We found 4/31 strains resistant to metronidazole (13% of the preselected isolates, Table 1). Three of these 4 strains belonged to RT010 (MIC=4 mg/L) and the fourth isolate belonged to RT016 (MIC=2 mg/L). All of these strains were also identified as resistant in the initial susceptibility testing in Leeds. The interlaboratory difference in antimicrobial susceptibility may be explained by differences in testing methodology, but were not further investigated here.

To determine whether the observed resistance was due to the presence of the pCD-METRO plasmid, we performed a reference assembly of the sequence reads obtained from whole genome sequencing of these isolates against the pCD-METRO reference sequence (obtained from the European Nucleotide Archive BioProject number PRJEB24167). No reliable mapping of reads to the reference sequence was found and – in line with this finding – the strains were negative in a PCR assay directed against pCD-METRO (data not shown).¹⁰ We therefore conclude that these strains do not carry pCD-METRO and that a different mechanism confers metronidazole resistance in these isolates.

Resistance to metronidazole is medium dependent

We have previously described a strain that demonstrated medium-dependent metronidazole resistance (MIC=4 mg/L) independent of pCD-METRO.¹⁰ In order to test if the metronidazole resistant phenotype of the four strains from the COMBACTE-CDI study could similarly be medium-dependent, strain GSK241 (MIC=4 mg/L) was plated on BHI agar that is routinely used in our laboratory, BBA (containing 5% defibrinated sheep blood, 1 µg/ml vitamin K and 5 µg/ml hemin), and BHI blood agar (BHI agar supplemented with 5% defibrinated sheep blood, 1 µg/ml vitamin K

and 5 µg/ml hemin) after which a metronidazole E-test was applied. We found that strain GSK241 was susceptible to metronidazole (MIC=0.25 mg/L) on BHI medium but resistant (MIC≥2 mg/L) on both BBA agar and BHI blood agar (Figure 1). These results indicate that components present in blood agar are responsible for this medium-dependent resistant phenotype.

We wondered whether the medium-dependent change in MIC values was a general characteristic of *C. difficile* irrespective of the resistance phenotype, or specific to the resistant strains. For this reason, we tested selected COMBACTE-CDI strains by E-test on both BHI agar and BBA (Table 2). All strains were clearly susceptible on BHI agar (MIC < 0,5 mg/L) but, with the exception of GSK234, showed a 4-to-32-fold increase in MIC when tested on BBA compared to BHI agar. This medium-dependent increase in MIC was not restricted to a specific RT, as the phenotype was seen for strains belonging to diverse types (RT010, RT016, RT018, RT027, RT176, RT181 and RT198).

Taken together, our data suggest that components present in BBA/BHI blood agar result in reduced susceptibility of strains to metronidazole through a general mechanism. In the case of strains GSK184, GSK241, GSK242NEW and GSK313 this leads to these strains being qualified as metronidazole resistant.

Heme is required for medium-dependent differences in metronidazole susceptibility

The fact that the medium-dependent increase in MIC was observed for both BBA and BHI blood agar (Figure 1) suggests that the phenotype is independent of the base broth and is likely to be mediated by the supplementation with vitamin K, hemin, and/or blood.

For practical purposes, we evaluated the effect of hemin on the metronidazole resistance phenotype of strains GSK64 (metronidazole susceptible) and GSK241 (metronidazole resistant). We found that supplementation of BHI with 5 µg/ml hemin raised the metronidazole MIC to levels similar to those observed for the BBA and BHI blood agar plates (Table 2; Figure 2A).

We extended this finding to a selection of COMBACTE-CDI strains and found that, with the exception of strain GSK234, all tested strains showed an 8-to-24-fold increase in metronidazole MIC on BHI supplemented with hemin compared to BHI alone (Table 2). These results mirror those obtained for the E-test on BBA, indicating that hemin is the main determinant of medium-dependent differences in metronidazole MIC for these strains. Under our experimental conditions, the hemin-dependent increase in MIC appears to be specific to metronidazole, as no increase in MIC was observed for vancomycin (Figure 2A).

We next assessed the MIC of both metronidazole and vancomycin of strains GSK64 and GSK241 with a range of 0-15 µg/ml hemin. Both strains show a gradual increase in MIC for metronidazole that in the case of GSK241 saturates at > 5µg/ml hemin; the MIC for GSK64 appears to increase further at higher concentration of hemin. In contrast, no increase in vancomycin MIC was seen even in the presence of the highest concentrations of hemin tested (Figure 2B).

Altogether these results demonstrate that the presence of heme is crucial for a medium-dependent resistance phenotype in *C. difficile* and that this appears to be specific for metronidazole.

An *hsmA* genetic signature is associated with increase metronidazole MICs in PCR ribotype 010 strains

Recent work has shown that four genes (*hsmA*, *hsmR*, *hatT*, *hatR*) are differentially regulated in response to heme, and that the products of the *hsmAR* operon improve growth of a *C. difficile* PCR ribotype 027 strain in the presence of metronidazole.^{29, 30} For this reason we performed a single nucleotide polymorphism (SNP) analysis on the genes *hatR*, *hatT*, *hsmR* and *hsmA* using the sequences from the RT027 strain R20291 (GenBank accession FN545816) as a reference.

Using variant positions, we identified signatures for these genes for each strain from the COMBACTE-CDI collection. In the case of *hatR*, *hatT* and *hsmR* these signatures were conserved

within a PCR ribotype, and even across closely related PCR ribotypes (e.g RT027, RT198, RT181 and RT176 share the same signatures) (Supplementary Table 1). However, for *hsmA*, we observed two distinct but related signatures within a single PCR ribotype. SNPs were identified in the 399-bp *hsmA* gene at positions 129, 249, 366, 372 and 392, resulting in a 5-base pair signature sequence. This signature is GGCAT for the RT027 and RT027-like isolates, TGTAC in RT002 and RT018 isolates and TATAC in some RT010 isolates (Figure 3A). Interestingly, the signature sequence TAT-C was found in all 3 metronidazole resistant RT010 isolates. The deletion at position 372 results in a frameshift and alters the primary amino acid sequence of the C-terminus of the HsmA protein.

In order to validate the significance of the signature, we performed the same *hsmA* SNP analysis on whole genome sequences obtained from another collection of isolates enriched for metronidazole resistance.¹⁰ This collection contains RT010, RT020 and RT027 isolates which have been characterised with respect to metronidazole MIC and pCD-METRO carriage. We expected to find a similar clustering of *hsmA* signature sequence and PCR ribotype and predicted that the previously described RT010 isolate showing medium-dependent resistance (MIC=4 mg/L) would carry the 1-bp deletion in *hsmA*. Indeed, we found this was the case (Figure 3B). Strikingly, all highly resistant RT010 strains that carried pCD-METRO also contained the TAT-C *hsmA* signature sequence (Figure 3B).

We wondered how frequently this deletion could be found in RT010 isolates, as metronidazole resistance is most commonly observed in this RT. For this reason, we performed whole genome SNP (wgSNP) analysis through the Enterobase platform on sequences available in the Sequence Read Archive (SRA) of multilocus sequence type 15 (ST15; which includes RT010) (n=57) and ST15-like strains (n=4) as well as the sequences of the RT010 isolates described earlier in this study (n=21)¹⁰,²⁴⁻²⁶. We found that the TAT-C signature in *hsmA* was detected in a specific lineage of ST15- and ST15-like strains originating from different countries (Figure 4). One out of 61 (1.6%) of the ST15- and ST15-like isolates was found to contain the 1-bp *hsmA* deletion (accession number ERR125985),

244 but no metadata was available for this strain in the SRA to confirm metronidazole resistance.

245 Interestingly, pCD-METRO carriage is distributed throughout the lineage with the TAT-C *hsmA*

246 signature, suggesting that pCD-METRO may be preferentially acquired in strains with pre-existing

247 low-level metronidazole resistance.

248 Altogether our results demonstrate that a specific signature of *hsmA*, resulting in an altered C-

249 terminal protein sequence, is associated with heme-dependent metronidazole resistance as well as

250 pCD-METRO carriage in RT010 strains of *C. difficile*.

Discussion

In this study we describe a collection of clinical *C. difficile* isolates that demonstrate a heme-dependent increase in MIC to metronidazole and make the observation that four strains determined to be resistant to metronidazole required heme supplementation for this phenotype. Additionally, we show that a C-terminal deletion at position 372 in *hsmA* correlates to metronidazole resistance in RT010 isolates.

The observation that the MICs for certain antibiotics vary depending on the type of medium used has been well documented in other organisms, but little to no data is available for *C. difficile*.^{10, 31} One of the best known examples is the effect of divalent calcium on daptomycin susceptibility of a variety of organisms but other examples have been documented as well.³² For instance, *Escherichia coli* was sensitive to bleomycin in LB broth, but was resistant to this antibiotic in glucose minimal medium, though the mechanism behind this difference remains unclear.³³ Similar results were obtained for *Moellerella wisconsensis* and *Proteus* spp for fosfomycin resistance when comparing MICs on IsoSensitest broth and (cation-adjusted) Mueller Hinton broth.^{34, 35} Additionally, medium-dependent activity of gentamicin sulfate against enterococci has also been encountered, showing medium-dependent activity of antibiotics against bacteria is not a phenomenon restricted to gram-negative organisms.³⁶

In this study we observed that almost all strains showed an increase in metronidazole MIC when grown on blood agar compared to BHI (Figure 1, Table 2). We note the limitation that the COMBACTE-CDI collection we analysed here does not encompass an unbiased collection of PCR ribotypes, and in particular clade 2 strains (RT016, RT027, RT176, RT181, RT198) appear to be overrepresented. We found that heme supplemented to the blood agar plates was the causative determinant for this phenotype (Figure 2, Table 2), presumably through the ability of heme to detoxify the nitro-radicals generated by metronidazole activation.³⁷ As lethal concentrations of antimicrobials are thought to generate toxic radicals by altering cellular metabolism, we expected to

find heme-dependent alterations in antibiotic susceptibility for other antibiotics than metronidazole.
^{38, 39} However, no heme-dependent reduction in vancomycin susceptibility was found in our study,
 suggesting that the effect of heme shows specificity for metronidazole under the conditions tested.

Elegant work by Knippel *et al.* has demonstrated that reduced metronidazole susceptibility upon
 heme supplementation in R20291 was largely mediated by the *hsmRA* operon, leading to the
 question whether presence/absence or sequence variants of these genes underlie heme-dependent
 resistance in other RTs. ²⁹ Based on the present dataset, however, we were unable to identify
 specific sequence variants of this operon (or in the *hatRT* operon also involved in heme
 detoxification) that could explain why the vast majority of strains are less susceptible to
 metronidazole upon heme supplementation. The genes appear to be (near-)universally conserved
 amongst different *C. difficile* types (data not shown) and the same signature is found in strains that
 do or do not respond to heme supplementation, and those that do or do not qualify as resistant
 (Table 1, Table 2, Supplemental Table 1). These results imply that other factors than the genome
 sequence of the *hatRT* and *hsmRA* operons can contribute to heme-dependent reduction in
 metronidazole susceptibility.

Nevertheless, we did identify a C-terminal deletion in *hsmA* that correlated to heme-dependent
 metronidazole resistance in RT010 (ST15) isolates (Figure 3, Figure 4). Isolates without this deletion
 did become less susceptible to metronidazole in presence of heme, but did not exceed the EUCAST
 criterium for resistance to this antibiotic. ²⁰ We validated our findings in the collection of clinical
 isolates used in the pCD-METRO study. ¹⁰ At present, there is no structural information on the HsmA
 protein, though homology between the protein and heme-containing cytochromes has been noted.
²⁹ HsmA has been postulated to act through sequestration of heme, but the effect of the altered C-
 terminal sequence on the affinity for heme remains to be elucidated.

The COMBACTE-CDI collection analysed here includes a limited number of strains per RT (Table 1). It
 will be interesting to see whether targeted analyses of larger collections of specific ribotypes will

301 reveal additional sequence variants of *hsmAR* associated with reduced susceptibility or resistance to
302 metronidazole.

303 Our data hint at a possible cumulative effect of chromosomal and extrachromosomal determinants in
304 metronidazole resistance as strains carrying the pCD-METRO plasmid are dispersed over the
305 resistant ST15/ST15-like (RT010) lineage characterised by the TAT-C *hsmA* signature (Figure 4).
306 Strains that possess both the C-terminal adenine deletion in *hsmA* and the pCD-METRO plasmid have
307 a higher metronidazole MIC (MIC $\geq$ 8 mg/L vs 4 mg/L in the pCD-METRO negative RT010s). As no
308 pCD-METRO positive RT010 isolate containing the TATAC signature sequence was present in this
309 collection, we do not know if pCD-METRO carriage without the deletion can still result in an MIC of $\geq$
310 8 mg/L, though this appears to be the case in RT020 and RT027.¹⁰ Irrespective of the effect on
311 metronidazole MICs, pCD-METRO carriage is associated with the 1-bp deletion in *hsmA* in RT010
312 isolates. Though this might result from a selection bias (by preferentially characterizing isolates with
313 higher MICs), it is conceivable that the deletion facilitates pCD-METRO carriage in some way.

314 Our findings suggest that the heme-dependent reduction in metronidazole susceptibility is common
315 in *C. difficile* (Table 2). Though heme levels can be elevated at the host-pathogen interface during
316 CDI,³⁰ pathogenicity does not seem a requirement for the heme-dependent reduction in MIC as it is
317 also found in non-toxigenic strains such as those belonging to RT010. For the same reason, it is
318 unlikely that extensive and continued use of metronidazole provided the selective pressure for the
319 acquisition and/or persistence of this phenomenon during evolution.^{6, 7, 40} In the majority of the
320 strains the MIC will likely not be raised over the EUCAST cut-off (2 mg/L) for resistance,²⁰ but they
321 clearly do become less susceptible to metronidazole. Due to absorption in the small intestine and
322 sequestration- or inactivation of the microbiota, levels of metronidazole at the end of the colon are
323 potentially low as determined by concentrations found in fecal material.⁴¹⁻⁴⁴ It is therefore quite
324 possible that a moderate increase in metronidazole MIC could in fact facilitate growth of *C. difficile*
325 in patients treated with metronidazole. Whether or not heme-dependent reduced susceptibility

326 plays a role in treatment failure (that does not appear to correlate with metronidazole resistance)
327 remains to be established.^{10, 45}

328 An important implication of our findings is that a well-described testing method in diagnostic
329 antimicrobial susceptibility testing is of the utmost importance. The type of media and
330 supplementation used can influence the MIC of certain antibiotics as we have demonstrated for
331 heme supplementation and metronidazole susceptibility. It is our experience that small
332 interlaboratory differences in standard operating procedures exist despite conforming to CLSI
333 standards, which may explain the differences in MICs sometimes found between institutions. As
334 medium-dependent differences in antimicrobial susceptibility may be both antibiotic- and organism-
335 specific, this argues for a standardised method per genus rather than a standard testing method for
336 all anaerobic organisms.

337 In conclusion, we have demonstrated that heme is the causative agent of medium-dependent
338 reduction in metronidazole susceptibility in clinical *C. difficile* isolates of different ribotypes, but does
339 not influence vancomycin susceptibility. Additionally, we have found a deletion in the C-terminal
340 part of *hsmA* which correlates to metronidazole resistance in RT010 isolates.

341

342 **Acknowledgements**

343 We would thank the members of the COMBACTE-CDI Consortium for providing the *C. difficile*
344 isolates and FASTQ files that were used in this study. The authors thank J. Corver and B. Hornung for
345 helpful discussions.

346 **Funding**

347 The COMBACTE-CDI project receives support from the Innovative Medicines Initiative 2 Joint
348 Undertaking (Grant Agreement no 777362). Work in the group of WKS is supported by a Vidi
349 fellowship (864.13.003) from the Netherlands Organisation for Scientific Research, and intramural
350 funding from Leiden University Medical Center.

351 **Transparency declaration**

352 The COMBACTE-CDI consortium includes partners GSK, Pfizer, DaVolterra, AstraZeneca, Sanofi
353 Pasteur and bioMérieux. The companies did not have a role in the design and execution of the
354 experiments for this study but provided the WGS of the isolates (GSK) and allowed examination of
355 the FASTQ files (bioMérieux). Conceived the study: IMB, EJK, JF, WKS. Performed experiments: IMB,
356 CH, IMJGBS, BS, EC, JF. Analysed data: IMB, SN, IAS, VV, KD, JF, WKS. Drafted manuscript: IMB, WKS.
357 All authors edited and approved the final version of the manuscript.

358

References

1. Chang JY, Antonopoulos DA, Kalra A et al. Decreased diversity of the fecal Microbiome in recurrent *Clostridium difficile*-associated diarrhea. *The Journal of infectious diseases* 2008; **197**: 435-8.
2. Smits WK, Lyras D, Lacy DB et al. *Clostridium difficile* infection. *Nat Rev Dis Primers* 2016; **2**: 16020.
3. Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nature reviews Microbiology* 2009; **7**: 526-36.
4. Ooijselaar RE, van Beurden YH, Terveer EM et al. Update of treatment algorithms for *Clostridium difficile* infection. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2018; **24**: 452-62.
5. McDonald LC, Gerding DN, Johnson S et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2018; **66**: 987-94.
6. Clancy CJ, Buehrle D, Vu M et al. Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America clinical practice guidelines on the treatment of *Clostridium difficile* infections in the United States. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2020.
7. Crowell KT, Julian KG, Katzman M et al. Compliance with *Clostridium difficile* treatment guidelines: effect on patient outcomes. *Epidemiol Infect* 2017; **145**: 2185-92.
8. Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms. *The Journal of antimicrobial chemotherapy* 2018; **73**: 265-79.
9. Lofmark S, Fang H, Hedberg M et al. Inducible metronidazole resistance and nim genes in clinical *Bacteroides fragilis* group isolates. *Antimicrobial agents and chemotherapy* 2005; **49**: 1253-6.
10. Boekhoud IM, Hornung BVH, Sevilla E et al. Plasmid-mediated metronidazole resistance in *Clostridioides difficile*. *Nature Communications* 2020; **11**: 598.
11. Piepenbrock E, Stelzer Y, Berger F et al. Changes in *Clostridium* (*Clostridioides*) *difficile* PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years. *Curr Microbiol* 2019; **76**: 520-6.
12. Moura I, Monot M, Tani C et al. Multidisciplinary analysis of a nontoxigenic *Clostridium difficile* strain with stable resistance to metronidazole. *Antimicrobial agents and chemotherapy* 2014; **58**: 4957-60.
13. Arcay RM, Suárez-Bode L, López-Causapé C et al. Emergence of high-level and stable metronidazole resistance in *Clostridioides difficile*. *International journal of antimicrobial agents* 2020; **55**: 105830.
14. Lynch T, Chong P, Zhang J et al. Characterization of a stable, metronidazole-resistant *Clostridium difficile* clinical isolate. *PloS one* 2013; **8**: e53757.
15. Deshpande A, Wu X, Huo W et al. Chromosomal Resistance to Metronidazole in *Clostridioides difficile* can be Mediated by Epistasis Between Iron Homeostasis and Oxidoreductases. *Antimicrobial agents and chemotherapy* 2020: AAC.00415-20.
16. Stubbs SL, Brazier JS, O'Neill GL et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of *Clostridium difficile* and construction of a library consisting of 116 different PCR ribotypes. *Journal of clinical microbiology* 1999; **37**: 461-3.
17. Freeman J, Vernon J, Pilling S et al. The CloSER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent *Clostridium difficile* ribotypes, 2011-2014. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2018; **24**: 724-31.

18. Fawley WN, Knetsch CW, MacCannell DR et al. Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for *Clostridium difficile*. *PLoS one* 2015; **10**: e0118150.
19. CLSI. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eighth edition. Wayne, PA.: Clinical and Laboratory Standards Institute, 2012; 56.
20. EUCAST. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0, 2018.
http://www.eucast.org/clinical_breakpoints/.
21. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature methods* 2012; **9**: 357-9.
22. Li H, Handsaker B, Wysoker A et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009; **25**: 2078-9.
23. Robinson JT, Thorvaldsdóttir H, Wenger AM et al. Variant Review with the Integrative Genomics Viewer. *Cancer Res* 2017; **77**: e31-e4.
24. Hornung BVH, Kuijper EJ, Smits WK. An in silico survey of *Clostridioides difficile* extrachromosomal elements. *Microb Genom* 2019.
25. Frentrup M, Zhou Z, Steglich M et al. A publicly accessible database for *Clostridioides difficile* genome sequences supports tracing of transmission chains and epidemics. *Microb Genom* 2020; **6**.
26. Zhou Z, Alikhan NF, Mohamed K et al. The Enterobase user's guide, with case studies on *Salmonella* transmissions, *Yersinia pestis* phylogeny, and *Escherichia* core genomic diversity. *Genome research* 2020; **30**: 138-52.
27. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* 2014; **30**: 1312-3.
28. Fawley WN, Wilcox MH. Molecular epidemiology of endemic *Clostridium difficile* infection. *Epidemiology and infection* 2001; **126**: 343-50.
29. Knippel RJ, Wexler AG, Miller JM et al. *Clostridioides difficile* Senses and Hijacks Host Heme for Incorporation into an Oxidative Stress Defense System. *Cell Host Microbe* 2020.
30. Knippel RJ, Zackular JP, Moore JL et al. Heme sensing and detoxification by HatRT contributes to pathogenesis during *Clostridium difficile* infection. *PLoS Pathog* 2018; **14**: e1007486.
31. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in *Clostridium difficile*. *The Journal of antimicrobial chemotherapy* 2008; **62**: 1046-52.
32. Fuchs PC, Barry AL, Brown SD. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. *Diagnostic microbiology and infectious disease* 2000; **38**: 51-8.
33. Xu T, Brown W, Marinus MG. Bleomycin Sensitivity in *Escherichia coli* is Medium-Dependent. *PLoS one* 2012; **7**: e33256.
34. Stock I, Falsen E, Wiedemann B. *Moellerella wisconsensis*: identification, natural antibiotic susceptibility and its dependency on the medium applied. *Diagnostic microbiology and infectious disease* 2003; **45**: 1-11.
35. Stock I. Natural antibiotic susceptibility of *Proteus* spp., with special reference to *P. mirabilis* and *P. penneri* strains. *J Chemother* 2003; **15**: 12-26.
36. Raymond EA, Traub WH. Medium-dependent activity of gentamicin sulfate against enterococci. *Appl Microbiol* 1971; **21**: 192-4.
37. Asard H, Barbaro R, Trost P et al. Cytochromes b561: ascorbate-mediated trans-membrane electron transport. *Antioxid Redox Signal* 2013; **19**: 1026-35.
38. Kohanski MA, Dwyer DJ, Hayete B et al. A common mechanism of cellular death induced by bactericidal antibiotics. *Cell* 2007; **130**: 797-810.
39. Boekhoud IM, Michel AM, Corver J et al. Redefining the *Clostridioides difficile* $\sigma(B)$ Regulon: $\sigma(B)$ Activates Genes Involved in Detoxifying Radicals That Can Result from the Exposure to Antimicrobials and Hydrogen Peroxide. *mSphere* 2020; **5**.

40. Beinortas T, Burr NE, Wilcox MH et al. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. *The Lancet Infectious diseases* 2018; **18**: 1035-44.
41. Johnson S, Homann SR, Bettin KM et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. *Ann Intern Med* 1992; **117**: 297-302.
42. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. *Gut* 1986; **27**: 1169-72.
43. Tally FP, Goldin B, Sullivan NE. Nitroimidazoles: in vitro activity and efficacy in anaerobic infections. *Scandinavian journal of infectious diseases Supplementum* 1981; **26**: 46-53.
44. Nagy E, Foldes J. Inactivation of metronidazole by Enterococcus faecalis. *The Journal of antimicrobial chemotherapy* 1991; **27**: 63-70.
45. Baktash A, Terveer EM, Zwittink RD et al. Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. *Frontiers in microbiology* 2018; **9**: 1242.

Figure 1. Medium-dependent resistance to metronidazole is independent of base broth. Strain GSK241 was grown and resuspended to 2.0 McFarland turbidity and spread on BHI agar, Brucella Blood Agar (supplemented with 1 µg/ml vitamin K and 5 µg/ml hemin) and BHI Blood Agar (BHI broth supplemented with 5% sheep blood, 1 µg/ml vitamin K and 5 µg/ml hemin). An E-test was placed and plates were incubated for 48h prior to imaging. Red lines indicate the epidemiological cut-off value for metronidazole as determined by EUCAST and have been used to determine resistance in this study²⁰. Numbers between brackets at the top of the image correspond to the reported MIC value on BHI agar, Brucella blood agar and BHI blood agar, respectively.

Figure 2. Heme supplementation increases the MICs to metronidazole, but not to vancomycin. A)

Strains GSK64 and GSK241 were resuspended in PBS to 2.0 McFarland turbidity and plated on BHI agar and on BHI agar supplemented with 5 µg/ml hemin. Subsequently E-tests for metronidazole and vancomycin were applied and plates were incubated for 48h prior to imaging. Red lines indicate the epidemiological cut-off value for metronidazole as determined by EUCAST and have been used to determine resistance in this study²⁰. For a complete overview of the MICs to metronidazole of

492 these strains on BHI agar and BHI agar supplemented with hemin, see Table 2. **B)** Typical
 493 metronidazole (top) and vancomycin (bottom) E-test results performed on strains GSK64 (orange)
 494 and GSK241 (red) and when grown on BHI supplemented with various concentration of hemin (0;
 495 0.5; 1; 2.5; 5; 10; 15 mg/L). The dashed line indicates the epidemiological cut-off value for
 496 metronidazole and vancomycin as determined by EUCAST (2 mg/L).

Figure 3. TAT-C signature in *hsmA* correlates to metronidazole resistance in RT010 isolates. The horizontal black bars represent the median MIC. **A)** *hsmA* signature sequences based on SNP analysis in the COMBACTE-CDI clinical isolates. Strains containing the GGCAT signatures belong to RT016, RT027, RT176, RT181 and RT198. The TAT-C and TATAC signatures correspond to RT010 in this study, whereas RT002 and RT018 containing sequence TGTAC. **B)** *hsmA* signature based on SNP analysis in the clinical isolates sequenced in the pCD-METRO study¹⁰. The signature sequence GGCAT is found in RT027, TAT-C and TATAC in RT010 and TGTAC in RT012 and RT020.

Figure 4. The C-terminal deletion in *hsmA* is associated with a lineage of ST15 and ST15-like isolates. When available, metronidazole susceptibility data and pCD-METRO carriage are indicated as illustrated in the legend. Country flags prior to strain name indicate the strain origin, when known. Strain names¹⁰ or SRA accession numbers are included. Distances in tree are shown in logarithmic scale.

Isolate	Location of participant at time of sample	Country of origin	PCR ribotype	MIC (mg/L)
GSK234	Inpatient	Sweden	002	0.25
GSK6	Community doctor	UK	002	0.25
GSK7	Inpatient	UK	002	0.125
GSK22bis	Inpatient	UK	010	0.125
GSK211	Inpatient	Romania	010	0.25
GSK241	Inpatient	France	010	4
GSK242new	Inpatient	France	010	4
GSK246	Inpatient	France	010	0.5
GSK313	Inpatient	Spain	010	4
GSK184	Inpatient	Poland	016	2
GSK39	Community doctor	Italy	018	0.5
GSK302	Inpatient	Italy	018	0.5
GSK303	Inpatient	Italy	018	0.25
GSK54	Inpatient	UK	027	0.25
GSK55	Inpatient	Romania	027	0.25
GSK60	Inpatient	Poland	027	0.5
GSK61	Inpatient	Poland	027	0.5
GSK62	Inpatient	Poland	027	0.5
GSK63	Inpatient	Poland	027	0.5
GSK64	Inpatient	Poland	027	0.5
GSK65	Inpatient	Poland	027	0.5
GSK179	Inpatient	Poland	027	0.5
GSK318	Inpatient	Poland	027	0.5
GSK325	Inpatient	Poland	027	0.5
GSK327	Inpatient	Poland	027	0.5
GSK258	Inpatient	Slovakia	176	0.5
GSK110	Inpatient	Romania	181	0.5
GSK113	Inpatient	Romania	181	0.25
GSK114	Inpatient	Poland	198	0.5
GSK180	Community doctor	Romania	181	0.5
GSK190	Inpatient	Romania	181	0.25

511

512 **Table 1. Characteristics of the strains from this study.** MIC refers to the minimal inhibitory
513 concentration for metronidazole as determined by agar dilution at the Leiden University Medical
514 Center (see Materials and Methods).

515

Strain name	PCR Ribotype	E-test MIC BHI	E-test MIC BBA	E-test MIC BHI + hemin
GSK234	002	0.064	0.064	0.064
GSK241	010	0.25	4	6
GSK242new	010	0.25	6	6
GSK313	010	0.38	4	8
GSK246	010	0.125	1	1
GSK184	016	0.25	2	ND
GSK39	018	0.125	1.5	1
GSK318	027	0.125	1	1
GSK327	027	0.125	2	2
GSK325	027	0.125	1.5	ND
GSK60	027	0.125	4	ND
GSK61	027	0.125	2	1.5
GSK62	027	0.094	1.5	ND
GSK63	027	0.125	1.5	ND
GSK64	027	0.125	1.5	1.5
GSK65	027	0.094	1	ND
GSK179	027	0.125	1.5	ND
GSK258	176	0.16	1	1.5
GSK110	181	0.125	1	1.5
GSK180	181	0.094	1	1
GSK114	198	0.125	2	2

516

517 **Table 2. Metronidazole minimal inhibitory concentrations on different agar media as determined**
518 **by E-test.** Strains were tested on BHI agar, BHI agar supplemented with 5 µg/ml hemin or BBA as
519 determined by E-test. ND = not determined. MIC = minimal inhibitory concentration of
520 metronidazole under the conditions tested